Increased hepatitis C virus load among injection drug users infected with human immunodeficiency virus and human T lymphotropic virus type II

Journal of Infectious Diseases

Volumn 188, Issue 6, 2003, Pages 891-897

  Hisada, Michie ^a   Chatterjee, Nilanjan ^a   Zhang, Mingdong ^a   Battjes, Robert J ^b,c   Goedert, James J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c FRIENDS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 2; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; RNA ANALYSIS; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; VIRUS INFECTION; VIRUS LOAD;

ADULT; AGED; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV INFECTIONS; HIV-1; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 0141840749     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/377585     Document Type: Article

References (36)

1. International Agency for Research on Cancer (IARC). Hepatitis C virus. In: Monographs on the evaluation of carcinogenic risks to humans. Vol. 59. Hepatitis viruses. Lyon, France: IARC, 1994:165-221.
2. International Agency for Research on Cancer (IARC). Human immunodeficiency viruses. In: Monographs on the evaluation of carcinogenic risks to humans. Vol. 67. Human immunodeficiency viruses and human T-cell lymphotropic viruses. Lyon, France: IARC, 1996:1-390.
3. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in muhitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6:602-10.
4. Hisada M, O'Brien TR, Rosenberg PS, Goedert JJ. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. Multicenter Hemophilia Cohort Study. J Infect Dis 2000; 181:1475-8.
5. Daar ES, Lynn H, Donfield S, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. Hemophilia Growth and Development Study. J Acquit Immune Defic Syndr 2001; 26:466-72.
6. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficienvy virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34:1193-9.
7. Goedert JJ, Hatzakis A, Sherman KE, Eyster ME. Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection. Multicenter Hemophilia Cohort Study. J Infect Dis 2001; 184:1202-5.
8. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-9.
9. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96:179-83.
10. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33:240-7.
11. Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100:1584-9.
12. Briggs NC, Battjes RJ, Cantor KP, et al. Seroprevalence of human T cell lymphotropic virus type II infection, with or without human immunodeficiency virus type 1 coinfection, among US intravenous drug users. J Infect Dis 1995; 172:51-8.
13. Kato N, Nakazawa T, Mizutani T, Shimotohno K. Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection. Biochem Biophys Res Commun 1995; 206:863-9.
14. Goedert JJ, Fung MW, Felton S, Battjes RJ, Engels EA. Cause-specific mortality associated with HIV and HTLV-II infections among injection drug users in the USA. AIDS 2001; 15:1295-302.
15. Battjes RJ, Pickens RW, Brown LS Jr. HIV infection and AIDS risk behaviors among injecting drug users entering methadone treatment: an update. J Acquit Immune Defic Syndr Hum Retrovirol 1995; 10:90-6.
16. Wiktor SZ, Alexander SS, Shaw GM, et al. Distinguishing between HTLV-I and HTLV-II by western blot. Lancet 1990; 335:I533.
17. Goedert JJ, Hatzakis A, Maloney EM, Eyster EM. Increased liver decompensation risk with atypical hepatitis C virus antibody levels. Multicenter Hemophilia Cohort Study. J Infect Dis 2000; 182:590-4.
18. Korn EL, Graubard BI. Basic survey methodology. In: Korn EL, Graubard BI, eds. Analysis of health surveys. New York, NY: John Wiley & Sons, 1999:8-60.
19. Cleveland WS, Grosse E, Shyu WM. Local regression models. In: Chambers JM, Hastie TJ, eds. Statistical models in S. Pacific Grove, CA: Wadsworth & Brooks/Cole Advanced Books and Software, 1992:309-76.
20. Luwel K, Beem AL, Onghena P, Verschaffel L. Using segmented linear regression models with unknown change points to analyze strategy shifts in cognitive tasks. Behav Res Methods Instrum Comput 2001; 33:470-8.
21. Eforn B, Tibshirani RJ. An introduction t0 the bootstrap. In: Cox DR, Hinkley DV, Reid, N, Rubin DB, Silverman BW, eds. Monographs on statistics and applied probability. Vol 57. London: Chapman & Hall, 1998:I-425.
22. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood 1994; 84:1020-3.
23. Murphy EL, Glynn SA, Fridey J, et al. Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study. Arch Intern Med 1999; 159:1485-91.
24. Boschi-Pinto C, Stuver S, Okayama A, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis 2000; 181:35-41.
25. Casseb J. Possible mechanism for positive interaction of human T cell leukemia type I on liver disease. J Infect Dis 2000; 181:379-80.
26. Kishihara Y, Furusyo N, Kashiwagi K, Mitsutake A, Kashiwagi S, Hayashi J. Human T lymphotropic virus type 1 infection influences hepatitis C virus clearance. J Infect Dis 2001; 184:1114-9.
27. Fabrizi F, Martin P, Dixit V, et al. Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. Nephron 1998; 80:428-33.
28. Matthews-Greer JM, Caldito GC, Adley SD, et al. Comparison of hepatitis C viral loads in patients with or without human immunodeficiency virus. Clin Diagn Lab Immunol 2001; 8:690-4.
29. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection. JAMA 2000; 284:450-6.
30. Thio CL, Thomas DL, Goedert JJ, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001; 184:16-21.
31. Thio CL, Gao X, Goedert JJ, et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002; 76:4792-7.
32. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002; 359:1478-83.
33. Tachibana N, Okayama A, Ishihara S, et al. High HTLV-I proviral DNA level associated with abnormal lymphocytes in peripheral blood from asymptomatic carriers. Int J Cancer 1992; 51:593-5.
34. Gandhi M, Bacchetti P, Miotti P, Guinn TC, Veronese F, Greenblatt RM. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis 2002; 35:313-22.
35. Kozik CA, Vaughn DW, Snitbhan R, Innis BL. Hepatitis B virus infection in Thai children. Trop Med Int Health 2000; 5:633-9.
36. Beld M, Penning M, van Putten M, et al. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood 1999; 94:1183-91.